Head and Neck Cancer Clinical Trial Pipeline: Analysis of

New York, USA, Oct. 10, 2022 (GLOBE NEWSWIRE) — Head and Neck Cancer Clinical Trial Pipeline: Analysis of 130+ Key Companies Working in the Domain | DelveInsight

Head and Neck Cancer pipeline constitutes 130+ key companies continuously working towards developing 150+ Head and Neck Cancer treatment therapies, analyzes DelveInsight

DelveInsight’s ‘Head and Neck Cancer Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline head and neck cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the head and neck cancer pipeline domain.

Key Takeaways from the Head and Neck Cancer Pipeline Report

• DelveInsight’s head and neck cancer pipeline report depicts a robust space with 130+ active players working to develop 150+ pipeline therapies for head and neck cancer treatment. 
• Key head and neck cancer companies such as Innate Pharma, GlaxoSmithKline, Debiopharm, Checkpoint Therapeutics, Quadriga BioSciences, Palleon Pharmaceuticals, Klus Pharma, Bicycle Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Memgen, I-Mab Biopharma, Intensity Therapeutics, Wellmaker Bio, SN BioScience, Carisma Therapeutics, Genentech, Pionyr Immunotherapeutics, Palleon Pharmaceuticals, SN BioScience, Bicycle Therapeutics, Inhibrx, Celldex Therapeutics, Carisma Therapeutics Inc, BioAtla, Jacobio Pharmaceuticals, Compugen, GeoVax, CytomX Therapeutics, PNP Therapeutics, Galectin Therapeutics, Cyteir Therapeutics, Merck KGaA, Boehringer Ingelheim, Transgene, iTeos Therapeutics SA,  IntraGel Therapeutics, Incyte Corporation, Cue Biopharma, Rubius Therapeutics, Alkermes, Corregene Biotechnology, NanoCarrier, Kura Oncology, Betta Pharmaceuticals, Arcus Biosciences, Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche, Vaccinex, Pfizer, BioNTech,  Purple Biotech, Novartis Oncology, Macrogenics, Aveta Biomics,…